Concurrently, activated NLG919 abolishes the immunosuppressive tumor environment by inhibiting indoleamine 2,3-dioxygenase 1 (IDO-1) and modulating the balance between the essential amino acid L-tryptophan and its metabolite L-kynurenine. This evidence concerns the gene IDO1 and neoplasm.